Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Share-based Compensation (2016 - 2026)

Champions Oncology has reported Share-based Compensation over the past 17 years, most recently at $423000.0 for Q1 2026.

  • Quarterly results put Share-based Compensation at $423000.0 for Q1 2026, up 65.23% from a year ago — trailing twelve months through Jan 2026 was $1.0 million (up 28.63% YoY), and the annual figure for FY2025 was $654000.0, down 41.5%.
  • Share-based Compensation for Q1 2026 was $423000.0 at Champions Oncology, up from $249000.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for CSBR hit a ceiling of $423000.0 in Q3 2023 and a floor of $9000.0 in Q4 2024.
  • Median Share-based Compensation over the past 5 years was $249000.0 (2025), compared with a mean of $236117.6.
  • Biggest five-year swings in Share-based Compensation: plummeted 83.02% in 2024 and later soared 2666.67% in 2025.
  • Champions Oncology's Share-based Compensation stood at $119000.0 in 2022, then tumbled by 55.46% to $53000.0 in 2023, then plummeted by 83.02% to $9000.0 in 2024, then soared by 2666.67% to $249000.0 in 2025, then soared by 69.88% to $423000.0 in 2026.
  • The last three reported values for Share-based Compensation were $423000.0 (Q1 2026), $249000.0 (Q4 2025), and $208000.0 (Q3 2025) per Business Quant data.